Marc Miravitlles Fernández I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases. Institutions of which they are part Main researcher Pneumology Vall Hebron Institut de Recerca Doctor Pneumology General Hospital Twitter Marc Miravitlles Fernández Twitter Institutions of which they are part Main researcher Pneumology Vall Hebron Institut de Recerca Doctor Pneumology General Hospital I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases.
I’m a Pulmonologist and Senior Researcher at the Vall d’Hebron University Hospital and the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain. I obtained my MD at the Universitat de Barcelona, Barcelona, Spain in 1986 and my PhD at the Universitat Autònoma de Bacelona in 1997. I trained as specialist in Respiratory Medicine at Vall d'Hebron Hospital. My primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. I served as Secretary General of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) from 1999 to 2003 and I was responsible for International Relationships of SEPAR from 2006 until 2012. I was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and I was the Guidelines Director of the ERS from 2015 to 2018. I have acted as a consultant and/or chair or author for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on diagnostic and treatment of exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. I am also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present) and coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012). I am the director of the reference center for diagnosis and treatment of AATD in the Hospital Vall d’Hebron and I am author of 498 publications listed in PubMed and a h-index of 73 (May 2020)
Projects Grup de Recerca en Pneumologia IP: Jaume Ferrer Sancho Collaborators: Sergi Martí Beltran, Marta Vicenta Arjona Perís, Christian Eduardo Romero Mesones, Maria Angeles Jiménez Fuentes, Mª Jose Jurado Luque, Marc Miravitlles Fernández, Ana Villar Gomez, Antonio Álvarez Fernandez, Victor Monforte Torres, Odile Romero Santo-Tomas, Miriam Barrecheguren Fernández, David Clofent Alarcón, Carles Bravo Masgoret, Mario Culebras Amigo, Fco. Javier Muñoz Gall, Gabriel Sampol Rubio, Maria Antonia Ramon Belmonte, Mercedes Pallero Castillo, Mª Jesús Cruz Carmona, Cristina Berastegui Garcia, Almudena Felipe Montiel, Gerard Orriols Torras, Victoria Ruiz De Miguel, Meritxell Boada Perez, David Espejo Castellanos, Manuel López Meseguer, David Soler Segovia, Susana Gómez Olles, Cristina Esquinas López, Berta Saez Gimenez, Grup de Recerca en Pneumologia, Iñigo Ojanguren Arranz, Eva Polverino , Alexa Gabriela Nuñez Dubon, Letizia Traversi Funding agency: AGAUR no fer servir-correcte 4301-37 Funding: 0.01 Reference: 2021 SGR 00788 Duration: 01/01/2022 - 31/12/2024 Caracterización y factores de riesgo de las SEcuelas PULmonares de los pacientes que superan una neumonía por COVID-19 (PULSE-COVID). IP: Fco. Javier Muñoz Gall Collaborators: Maria Angeles Jiménez Fuentes, Marc Miravitlles Fernández, David Clofent Alarcón, David Soler Segovia Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI21/01046 Duration: 01/01/2022 - 31/12/2024 Pendent IP: Marc Miravitlles Fernández Collaborators: Alexa Gabriela Nuñez Dubon Funding agency: Instituto de Salud Carlos III Funding: 53732 Reference: CM19/00215 Duration: 01/01/2020 - 22/04/2022 Estudio de patogénesis de la enfermedad oulmonar obstructiva crónica mediante técnicas de biología molecular y computacional: Una opción para nuevas modalidades de tratamiento. IP: Marc Miravitlles Fernández Collaborators: Miriam Barrecheguren Fernández, Cristina Esquinas López Funding agency: Instituto de Salud Carlos III Funding: 147620 Reference: PI18/01376 Duration: 01/01/2019 - 30/06/2023 Pagination Current page 1 Page 2 Next page › Last page »
